Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1515067 | 0.76 | GABRA1 (0.41) | GABRA1GABRB2 | |
| SCHEMBL28073430 | 0.72 | LOXL2 (0.36) | — | |
| SCHEMBL457987 | 0.72 | GABRA1 (0.30) | GABRA1GABRB2 | |
| SCHEMBL7061191 | 0.69 | CTSL (0.32) | — | |
| SCHEMBL16395479 | 0.68 | HTR2C (0.40) | — | |
| SCHEMBL7928568 | 0.68 | GABRA1 (0.33) | GABRA1GABRB2 | |
| SCHEMBL723360 | 0.68 | GABRA1 (0.33) | GABRA1GABRB2 | |
| SCHEMBL9559691 | 0.67 | GABRA1 (0.34) | GABRA1GABRB2 | |
| SCHEMBL5433953 | 0.67 | GABRA1 (0.48) | GABRA1GABRB2 | |
| SCHEMBL4790115 | 0.67 | IMPDH2 (0.33) | GABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8080570-B2 | α2B and α2C agonists | ALLERGAN, INC. (US) | 2011-12-20 | — | — | US | claimed |
| US-9708245-B2 | Fatty acid acylated salicylates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160083336-A1 | FATTY ACID ACYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2016-03-24 | — | — | US | disclosed |
| US-6667077-B1 | Liquid crystal of negative dielectric anisotropy, low voltage driving and high quality display are made compatible | HITACHI, LTD. (JP) | 2003-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083336-A1 | FATTY ACID ACYLATED SALICYLATES AND THEIR USES | FADS1, FASN, ALOX5 | GABRA1 769/4885GABRB2 904/4885POLB 3979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.